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Background: Outcomes of heart failure (HF) have improved dramatically with the use of blockers of the
sympathetic and renin-angiotensin-aldosterone systems, as well as with more prevalent use of implantable
cardiac defibrillators and cardiac resynchronization therapy. Despite these interventions, however, the
overall prognosis of HF patients remains poor. Recently, stimulation of the right cervical vagus nerve
in patients with symptomatic heart failure has been evaluated. Results suggest that vagal nerve stimulation
provides sustained improvement in left ventricular (LV) function and symptoms associated with HF. How-
ever, much remains to be learned about the risks and benefits of therapies that alter autonomic regulatory
function for the treatment of heart failure.
Methods: The Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure
(ANTHEM-HF) study has been designed to address several key clinical questions about the role of auto-
nomic regulation therapy (ART) in patients with LV dysfunction and chronic symptomatic heart failure.
Conclusions: ANTHEM-HF should provide additional and valuable information regarding the safety and
the relationship between the site and intensity of ART and its salutary effects on HF. (J Cardiac Fail
2013;19:655e660)
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655by inhibiting certain neurohormones with b-blockers,
angiotensin-converting enzyme (ACE) inhibitors, and aldo-
sterone receptor blockers underscores the important role
played by neurohormonal activation during the progression
of HF.4e8 However, despite these advances in the use of neu-
rohormonal blockade and more recently the use of implant-
able cardioverter-defibrillator9 and cardiac resynchronization
therapy (CRT) devices10 in the management of patients with
HF, the overall prognosis of these patients remains poor.11
Therefore, development of novel therapeutic approaches
for the treatment of HF remains crucial.
An approach that could further advance the neurohor-
monal and autonomic imbalance hypothesis in HF is the
improvement of autonomic regulatory function by vagal
nerve stimulation (VNS). Reduced vagal activity is associ-
ated with increased mortality in patients with HF,3,12 and
a number of investigators have shown that restoration of au-
tonomic regulatory function by VNS improves survival in
animal models of HF. Li et al13 randomized myocardial in-
farction (MI)einduced HF rats to vagal or sham stimulation
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10 s/min with an intensity adjusted to reduce heart rate
by 5%e8% (20e30 beats/min in rats). Compared with
sham stimulation, VNS was associated with a significant
improvement in left ventricular (LV) hemodynamics and re-
modeling as well as reduced neurohormonal activation.
This was associated with a significant decrease in mortality
in the VNS rats at 140 days, from 50% to 14% compared
with sham-stimulated rats.13 In the canine model of intra-
coronary microembolization-induced heart failure, VNS
significantly improved LV structure and function compared
with sham-operated animals, independently from the use of
b-blockers and additive to the effects of b-blockade.14 Sim-
ilar beneficial effects of VNS on LV remodeling were re-
ported also in the canine pacing model of HF.15 Dogs
randomized to pacing alone continued to increase their
LV dimensions, whereas those randomized to pacing and
VNS had a significant attenuation of LV remodeling. Inter-
estingly, these effects were seen in the absence of any heart
rate lowering effect of VNS, because both groups were sub-
jected to the same constant ventricular pacing.15 These data
suggest that the beneficial effects of VNS could be seen in-
dependently from HR lowering.
More recently, a multicenter open-label phase II safety
and feasibility study was reported with the use of right cer-
vical VNS synchronized to the cardiac cycle (Cardiofit Sys-
tem; BioControl Medical, Yehud, Israel).16 The study
occurred in 32 New York Heart Association (NYHA) func-
tional class IIeIV patients, aged 56 6 11 years, with LV
ejection fraction (LVEF) 23 6 8%. VNS was titrated to
a maximum stimulation amplitude of 5.5 mA, an HR reduc-
tion of 5e10 beats/min, or the development of intolerable
side effects. After 6 months, VNS was associated with a sig-
nificant improvement in NYHA functional class, quality of
life, 6-minute walk distance, LVEF, and LV systolic vol-
umes. These improvements were maintained at 1 year.
However, beneficial effects of VNS were accompanied by
serious adverse events in 41% of the patients, including
3 deaths and 2 device-related adverse events. Less serious
but nonetheless bothersome adverse effects included cough,
dysphonia, and pain related to stimulation of the right cer-
vical vagus nerve.
That open-label study suggested that chronic VNS could
provide favorable long-term beneficial effects on LV func-
tion that might translate into improved outcomes in patients
with HF. However, the study also raised several question
that need to be addressed:
1) Does stimulation of the left vagus have similar effects
on LV remodeling?
2) Are the beneficial effects of VNS independent of its
HR-lowering effects and additive to effects of beta-
blockers?
3) Could lower-amplitude VNS have the same beneficial
effect on LV remodeling while minimizing side effects?
4) Does VNS that is not synchronized to the cardiac cycle
have the same beneficial effect on LV remodeling whileeliminating acute and chronic risks associated with en-
docardial lead implantation?
5) Are the therapeutic effects of VNS dependent on the
etiology of LV dysfunction?
The Autonomic Neural Regulation Therapy to Enhance
Myocardial Function in Heart Failure (ANTHEM-HF)
study has been designed to address some of these key
questions.
Study Hypotheses
ANTHEM-HF is a feasibility study to demonstrate safety
and to investigate several key methodologic questions re-
garding ART for the treatment of patients with chronic
symptomatic heart failure and reduced left ventricular ejec-
tion fraction. The study will collect exploratory data to test
the following hypotheses:
1) Left or right VNS provides similar salutary effects on
LV remodeling in patients with HF.
2) The beneficial effects of VNS are independent from its
rate-lowering effects and additive to the effects of
b-blockade.
3) Lower-amplitude VNS improves LV function and HF
symptoms with an acceptable risk (risk-to-benefit ra-
tio).
4) The beneficial effects of VNS can be achieved without
synchronization to the cardiac cycle, obviating the need
for endocardial right ventricular sensing.
5) VNS has similar beneficial benefit effects in patients
with ischemic and nonischemic cardiomyopathy.
Methods
Study Design
ANTHEM-HF is an open-label multicenter study designed
to test the safety and feasibility of VNS in patients with chronic
HF.Device Description
The Cyberonics VNS Therapy System (Implantable Pulse
Generator model 103, lead model 304) will be used in this study.
This is the same system that is commercially available in the
United States and Europe for the treatment of epilepsy and de-
pression. The system consists of an implantable pulse generator,
a bipolar helical cuff lead, and an external programming system
(Figs. 1 and 2). The implantable pulse generator is capable of
delivering low-current electrical pulses with adjustable parame-
ters to stimulate the cervical vagus nerve. The bipolar stimula-
tion lead has 3 self-sizing helical cuffs, 2 of which contain
stimulation electrodes and 1 serving as an anchor to stabilize
the lead and reduce issues associated with cyclic stress and
strain. VNS parameters can be remotely programmed with the
use of an external programming system consisting of a model
201 programming wand and version 8 software running on
a model 250 handheld computer with Windows Mobile (2003
Fig. 1. VNS pulse generator implanted with lead, commercial
configuration.
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communicates with the pulse generator via telemetry, thereby en-
abling functional assessments (device diagnostics), noninvasive
programming, and data retrieval.
Device Implantation Procedure
Patients will be implanted with a VNS Therapy System subcu-
taneously. Following the commercial implantation procedure, the
lead will be placed on the left or right cervical vagus nerve in
the neck, and the lead body will be tunneled from the neck inci-
sion site to the pulse generator in the chest pocket. The lead
will be placed with distal electrode positioned distal to the pa-
tient’s head (anchor tether proximal to the head), which is the op-
posite of the commercial implant configuration for epilepsy and
depression.Fig. 2. Handheld progrStudy Objectives
The primary safety objective is the incidence of procedure and
device-related complications. The primary efficacy objective of
the study is to evaluate the effects of chronic VNS on the echocar-
diographic changes in LV end-systolic volume (LVESV) and
LVEF. Several other exploratory echocardiographic measurements
will also be made. The secondary objectives are changes in NYHA
functional class, Minnesota Living With Heart Failure quality of
life score, 6-minute walk distance, and NYHA functional class
at the end of 6 months of VNS. Several other measurements,
such as neurohormones, heart rate variability, baroreceptor sensi-
tivity slope, and health care utilization, will also be made as ex-
plorative analyses.
Study Population
A maximum of 60 subjects with NYHA functional class IIeIII
heart failure, aged $18 years, are eligible for enrollment and ran-
domization. At the time of enrollment into the study, subjects will
have been prescribed to optimal oral pharmacologic management
with stable b-blocker therapy for HF (as indicated and tolerated)
for $3 months, and all other oral pharmacologic therapy for HF
(as indicated and tolerated) for $1 month. Key inclusion criteria
include a LVEF #40%; LV end-diastolic diameter $50 mm and
!80 mm; QRS width #150 ms; physically capable of performing
6-minute walk test (6MWT) with a baseline 6MWT distance of
150e425 meters, being limited by HF symptoms.
Key exclusion criteria include:
 Heart failure due to congenital heart disease; mitral or aortic
valve disease; or hypertrophic obstructive cardiomyopathy or
infiltrative cardiomyopathy;
 Medical conditions including vasovagal syncope or vasode-
pressor syncope; congenital or acquired long QT syndrome;
recurrent nerve paralysis; carotid or vertebral vascular malfor-
mation; carotid murmur, vascular bruit, or carotid artery lesion;
severe vertebral cervical disease or limited neck mobility;
childbearing potential, pregnancy, or breast-feeding; presence
of autonomic or sensory neuropathy of any cause; diabetes
mellitus with measured hemoglobin A1c O8.0% in the past
60 days; untreated hypothyroidism or hyperthyroidism; or an-
ticipated life expectancy of !12 months;ammer and wand.
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cular accident, or transient ischemic attack within the past
90 days; refractory hypotension; asthma, severe chronic ob-
structive pulmonary disease; severe restrictive lung disease or
oxygen dependence; peptic ulcer disease or upper gastrointes-
tinal bleeding within the past 180 days;
 A treatment history of cardiac transplantation, coronary artery
bypass surgery (CABG), valve replacement or repair, aortic
surgery, or percutaneous coronary intervention (PCI) within
the past 90 days; CRT; subcutaneous thoracic implantation of
semi/permanent devices, such as vascular catheters; radiother-
apy for thyroid disease/cancer; previous neck surgery and re-
sultant scar formation that would interfere with the ability to
implant the study system; tracheotomy; hospitalization or
need for intravenous HF therapy within the past 30 days; sleep
apnea or sleep-disordered breathing therapies to maintain air-
way patency with or without oxygen supplementation; renal di-
alysis; use of investigational therapy within the past 90 days;
vagotomy; previous or existing VNS treatment; inability to tol-
erate the anesthesia required for VNS Therapy System implan-
tation;
 Anticipated intervention during the course of the study such as
cardiac surgery, cardiac transplantation, pacing, or CRT im-
plantation; or shortwave diathermy, microwave diathermy or
therapeutic ultrasound diathermy.Study Treatment
Currently, 10 sites are participating in the study; however, ad-
ditional sites may be added. Subjects who provide informed con-
sent are randomized to thoracic subcutaneous VNS Therapy
System implantation for either right or left cervical VNS. After
a 2-week post-implant recovery period, the device is activated.
Vagal nerve stimulation begins at an output current amplitude
of 0.25 mA, pulse frequency of 10 Hz, pulse width of 130 ms,
and duty cycle of 17.5% (14 s on/66 s off). Over the 10-week ti-
tration period, stimulation parameters are adjusted in a stepwise
fashion under continuous ECG monitoring during weekly ses-
sions to a pulse width of 250 us, a pulse frequency of 10 Hz,
and an output current amplitude of 1.5 - 3.0 mA, limited by acute
expression of VNS-related side effects such as activation of the
expiratory reflex (mild cough) or heart rate response (O 4
bpm). Once the titration period is complete, VNS therapy is sus-
tained for 26 weeks. Subjects will have 2 follow-up visits, at 13
and 26 weeks after titration.
Subjects are instructed regarding potential adverse device-
related effects and are provided a magnet to inhibit pulse gener-
ator stimulation in the event of any uncomfortable device-related
effects. Should subjects perform this intervention, they are in-
structed to contact the site investigator, who will assess whether
an adverse device-related effect has occurred and whether the
programmed settings should be changed.
Study Measurements
At each follow-up visit, the following assessments are made:
device system diagnostics and change in device parameters set-
tings if necessary; measurement of LVESD and LVESV; LVEF;
NYHA functional class; 6MWT; quality of life assessment
with the Minnesota Living With Heart Failure Questionnaire;
heart rate variability; baroreflex sensitivity slope (optional); B-
type natriuretic peptide (BNP), N-terminal pro-BNP, glomerularfiltration rate, norepinephrine, angiotensin II, and C-reactive pro-
tein; health care utilization; and adverse events.
Study Analysis
All transthoracic echo recordings and blood samples are sent to
a designated core laboratory facility for analysis. All adverse
events will be adjudicated by an independent clinical events com-
mittee, who will determine whether events are device related or
not device related.
In addition to testing the primary and secondary objectives of
the study, exploratory analyses will also be performed to evaluate
the safety and efficacy of VNS therapy based on a patient’s base-
line LVEF, baseline heart rate, heart rate lowering, and stimulation
intensity. These analyses will be used to generate hypotheses for
future studies.
Study Risks and Mitigations
VNS is known to affect the sinoatrial and atrioventricular nodes.
Although there is a risk that VNS during this study could cause
bradycardia and/or asystole, significant bradycardia has not been
observed clinically in HF patients using stimulation intensities
greater than those used in this study.16 The Cyberonics VNS Ther-
apy System has been used to treat O100,000 patients worldwide
with left VNS for epilepsy and depression. A reversible bradycar-
dia occurred in only 0.1% of patients. In this study, the intensity of
VNS is programmed to levels below the threshold for symptom-
atic bradycardia.
Very high-intensity VNS (10e20 mA) is also known to alter the
atrial refractory period, which might promote the initiation and
maintenance of atrial fibrillation (AF). In nonhuman studies, in-
tense right VNS has been observed to induce acute AF that is usu-
ally not sustained. Although AF has been reported rarely during
the acute phase of VNS in humans, a definite temporal relation-
ship between VNS and development has not been established. In
the present study, subjects are observed at weekly intervals during
the titration phase of VNS therapy for any possible adverse ef-
fects, including the development of AF. If AF occurs during
VNS and is considered to be due to VNS, the investigators are ad-
vised to use their clinical judgment regarding continuation of
ART.
Although all previous clinical and preclinical research has sug-
gested a beneficial effect of VNS on cardiac function and symp-
toms of HF, it is possible that VNS may worsen HF, and even
lead to cardiac decompensation. Subjects are observed closely
during the study for the development of any signs and symptoms
of worsening HF. In the event of worsening HF that is considered
due to VNS, the principal investigator may discontinue VNS.
All adverse events are reviewed by an independent data and
safety monitoring board (DSMB) to determine if the investiga-
tional therapy poses an unacceptable risk to subject safety. The
DSMB has the authority to halt the study to ensure subject safety.
Discussion
One of the hallmarks of HF is autonomic imbalance with
withdrawal of parasympathetic activity and increase in
sympathetic activity.17 Some of the physiologic manifesta-
tions of autonomic imbalance include a decrease in barore-
flex sensitivity and reduction in heart rate variability, both
of which are associated with increased mortality.13e15,18
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Moreover, acute decompensated HF is preceded by with-
drawal of parasympathetic activity.16,18 Thus the vagus
nerve appears to play an important role in the pathogenesis
of heart failure.
Cardiac efferent fibers constitute only a small portion of
the vagal trunk. Under normal circumstances, efferent vagal
impulses are conducted to the heart throughout the cardiac
cycle and mediate parasympathetic influence on heart rate
and local cardiac reflex processing via release of acetylcho-
line and other neurotransmitters. In addition to its effects on
the sinoatrial and atrioventricular nodes, the release of ace-
tylcholine by vagal efferents stimulates the muscarinic re-
ceptors in the myocardium. There is evidence in animals
and humans that stimulation of the local muscarinic recep-
tors in the heart inhibit norepinephrine release from adren-
ergic nerve terminals, and therefore muscarinic receptors in
the heart appear to play an important role in the local mod-
ulation of cardiac sympathetic activity in both normal and
HF patients.19e22 In HF, parasympathetic ganglionic trans-
mission is reduced, muscarinic receptor density and compo-
sition are altered, and acetylcholinesterase activity is
decreased. Therefore, a reduction in parasympathetic activ-
ity, as seen in HF, would further contribute to increase nor-
epinephrine in the heart with consequent long-term
deleterious effects. Interestingly, the salutary effects of
VNS on LV function and HF symptoms are not dependent
on a reduction in heart rate.1,15 These data provide support
for the role of other, nondromotropic, mechanisms that
have been proposed for the beneficial effects of VNS
seen in preclinical and clinical studies.
Studies have also shown some subtle differences in the
response to right and left VNS. In addition to reducing heart
rate, right cervical VNS has been shown to increase nitric
oxide activity and cause vasodilation. It also increases heart
rate variability, reduces systolic blood pressure, diminishes
sympathetic nervous system activation of T cells, reduces
reactive oxygen species, and decreases inflammation and fi-
brosis. Right cervical VNS also reduces renal sympathetic
nervous activity, resulting in renal arterial vasodilation
with a decrease in plasma renin activity and activation of
the renin-angiotensin-aldosterone system.23
Although the left vagal nerve may have a proportionally
lower number of cardiac efferent fibers than the right vagal
nerve, acetylcholine responses in cats have been observed
by the separate stimulation of the right or the left cervical
vagal nerves.24 In dogs, left cervical VNS has been ob-
served to decrease left stellate ganglion activity, morning
surge of heart rate, and pacing-induced paroxysmal atrial
tachycardia while having less of an impact on heart rate
than right cervical VNS.25 Thus, the preclinical data sup-
port left cervical VNS being safe and having salutary ef-
fects in chronic HF.
Summary
ANTHEM-HF is a feasibility study to investigate several
key methodologic questions regarding ART for thetreatment of patients with chronic symptomatic HF and re-
duced LVEF. The hypotheses being tested in ANTHEM-HF
will provide additional and valuable information regarding
the relationship between the site and intensity of VNS and
its effects on HF.Disclosures
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